Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.65 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.63 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171782 | 0.89 | IDO1 (0.68) | MAOBNR4A2MAPTHTTL3MBTL1 | |
| SCHEMBL16710559 | 0.88 | MAOB (0.52) | MAOBNR4A2MRGPRX4MAPTHTT | |
| SCHEMBL16710623 | 0.88 | MAOB (0.55) | MAOBNR4A2MRGPRX4MAPTHTT | |
| SCHEMBL13970685 | 0.86 | IDO1 (0.53) | MAOBNR4A2MRGPRX4MAPTHTT | |
| SCHEMBL12879351 | 0.85 | MAOB (0.65) | MAOBNR4A2MRGPRX4MAPTHTT | |
| SCHEMBL18161369 | 0.85 | MAOB (0.65) | MAOBNR4A2MRGPRX4MAPTHTT | |
| SCHEMBL5669711 | 0.84 | MAOB (0.74) | MAOBNR4A2MRGPRX4MAPTHTT | |
| SCHEMBL4700356 | 0.83 | NR4A2 (0.68) | MAOBNR4A2MRGPRX4MAPTHTT | |
| SCHEMBL31172140 | 0.82 | MAOB (0.76) | MAOBNR4A2MRGPRX4MAPTHTT | |
| SCHEMBL18164545 | 0.82 | MAOB (0.63) | MAOBNR4A2MRGPRX4MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | MAOB 2077/4885NR4A2 733/4885MRGPRX4 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.